• Vaccine Name: rVSV- SEBOV-GP and -VP40
• Target Pathogen: Ebola virus
• Target Disease: Ebola hemorrhagic fever
• Vaccine Ontology ID: VO_0004661
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• NP from Zaire Ebola virus gene engineering:
  • Type: Recombinant vector construction
  • Description: New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP (Marzi et al., 2011).
  • Detailed Gene Information: Click Here.
• VP40 from Zaire ebolavirus gene engineering:
  • Type: Recombinant vector construction
  • Description: New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP (Marzi et al., 2011).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001025
• Preparation: rVSV-expressing SEBOV-GP and -VP40 (Marzi et al., 2011; Falzarano et al., 2011).
• Immunization Route: Intramuscular injection (i.m.)

Guinea pig Response

• Vaccination Protocol: The guinea pigs were vaccinated intraperitoneally with a single dose of 2 ×10^5 PFU to guinea pigs of rVSV (Marzi et al., 2011).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: The guinea pigs were subsequently challenged with 1000 LD50 of GPA-ZEBOV [20] or boosted with the same dose of rVSV and challenged 3 weeks later (Marzi et al., 2011).
• Efficacy: After applying a 2-dose immunization approach, we observed an improved cross-protection rate, with 5 of 6 guinea pigs surviving the lethal ZEBOV challenge if vaccinated with rVSV-expressing SEBOV-GP and -VP40 (Marzi et al., 2011).